245 related articles for article (PubMed ID: 11502457)
1. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of prostate cancer: current status and future directions.
Lieberman R
Cancer Metastasis Rev; 2002; 21(3-4):297-309. PubMed ID: 12549768
[TBL] [Abstract][Full Text] [Related]
3. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia.
Bostwick DG; Qian J
Urology; 2001 Aug; 58(2 Suppl 1):91-3. PubMed ID: 11502458
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention for prostatic intraepithelial neoplasia.
Nelson PS; Gleason TP; Brawer MK
Eur Urol; 1996; 30(2):269-78. PubMed ID: 8875211
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.
Alberts SR; Blute ML
Urology; 2001 Apr; 57(4 Suppl 1):188-90. PubMed ID: 11295624
[TBL] [Abstract][Full Text] [Related]
6. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
Kang TY; Nichols P; Skinner E; Groshen S; Valin G; Ye W; Raghavan D
BJU Int; 2007 May; 99(5):1024-7. PubMed ID: 17244277
[TBL] [Abstract][Full Text] [Related]
7. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
[TBL] [Abstract][Full Text] [Related]
8. Prostatic intraepithelial neoplasia and prostate cancer.
Montironi R; Santinelli A; Mazzucchelli R
Panminerva Med; 2002 Sep; 44(3):213-20. PubMed ID: 12094135
[TBL] [Abstract][Full Text] [Related]
9. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
Alberts SR; Novotny PJ; Sloan JA; Danella J; Bostwick DG; Sebo TJ; Blute ML; Fitch TR; Levitt R; Lieberman R; Loprinzi CL
Am J Ther; 2006; 13(4):291-7. PubMed ID: 16858161
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for precancerous lesions of the prostate.
Hull D; Bostwick DG
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of prostate cancer. A review.
Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
[TBL] [Abstract][Full Text] [Related]
12. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer prevention trial yields positive results, but with a few cautions.
Reynolds T
J Natl Cancer Inst; 2003 Jul; 95(14):1030-1. PubMed ID: 12865442
[No Abstract] [Full Text] [Related]
15. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
16. The future of prostate cancer prevention.
Brawley OW; Barnes S; Parnes H
Ann N Y Acad Sci; 2001 Dec; 952():145-52. PubMed ID: 11795434
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]